The PI3K/AKT Pathway as a Target for Cancer Treatment

被引：654

作者：

Mayer, Ingrid A. ^{[1
,2
,3
]}

Arteaga, Carlos L. ^{[1
,2
,3
]}

机构：

[1] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA

[3] Vanderbilt Univ, Sch Med, Breast Canc Program, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA

来源：

ANNUAL REVIEW OF MEDICINE, VOL 67 | 2016年 / 67卷

关键词：

phosphoinositide 3-kinase (PI3K)/AKT; mammalian target of rapamycin (mTOR); pathway inhibitors; breast cancer; lymphoproliferative disorders; mutation; CHRONIC LYMPHOCYTIC-LEUKEMIA; POSITIVE BREAST-CANCER; RENAL-CELL CARCINOMA; PIK3CA MUTATIONS; PHOSPHOINOSITIDE; 3-KINASE; PHOSPHATIDYLINOSITOL; ESTROGEN DEPRIVATION; TYROSINE KINASE; MAMMARY-TUMORS; UP-REGULATION;

D O I：

10.1146/annurev-med-062913-051343

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.

引用

页码：11 / 28

页数：18

共 87 条

[1] Phosphatidylinositide Dependent Kinase Deficiency Increases Anxiety and Decreases GABA and Serotonin Abundance in the Amygdala [J].

Ackermann, Teresa F. ;

Hoertnagl, Heide ;

Wolfer, David P. ;

Colacicco, Giovanni ;

Sohr, Reinhard ;

Lang, Florian ;

Hellweg, Rainer ;

Lang, Undine E. .

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2008, 22 (5-6) :735-744

[2]

[Anonymous], SAN ANT BREAST CANC

[3]

Baselga J, 2013, P EUR CANC C

[4] Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Im, Seock-Ah ;

Clark, Emma ;

Ross, Graham ;

Kiermaier, Astrid ;

Swain, Sandra M. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) :3753-+

[5] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[6] Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors [J].

Bendell, Johanna C. ;

Rodon, Jordi ;

Burris, Howard A. ;

de Jonge, Maja ;

Verweij, Jaap ;

Birle, Diana ;

Demanse, David ;

De Buck, Stefan S. ;

Ru, Qinhua C. ;

Peters, Malte ;

Goldbrunner, Michael ;

Baselga, Jose .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) :282-290

[7] A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].

Berns, Katrien ;

Horlings, Hugo M. ;

Hennessy, Bryan T. ;

Madiredjo, Mandy ;

Hijmans, E. Marielle ;

Beelen, Karin ;

Linn, Sabine C. ;

Gonzalez-Angulo, Ana Maria ;

Stemke-Hale, Katherine ;

Hauptmann, Michael ;

Beijersbergen, Roderick L. ;

Mills, Gordon B. ;

de Vijver, Marc J. van ;

Bernards, Rene .

CANCER CELL, 2007, 12 (04) :395-402

[8] PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer [J].

Bosch, Ana ;

Li, Zhiqiang ;

Bergamaschi, Anna ;

Ellis, Haley ;

Toska, Eneda ;

Prat, Aleix ;

Tao, Jessica J. ;

Spratt, Daniel E. ;

Viola-Villegas, Nerissa T. ;

Castel, Pau ;

Minuesa, Gerard ;

Morse, Natasha ;

Rodon, Jordi ;

Ibrahim, Yasir ;

Cortes, Javier ;

Perez-Garcia, Jose ;

Galvan, Patricia ;

Grueso, Judit ;

Guzman, Marta ;

Katzenellenbogen, John A. ;

Kharas, Michael ;

Lewis, Jason S. ;

Dickler, Maura ;

Serra, Violeta ;

Rosen, Neal ;

Chandarlapaty, Sarat ;

Scaltriti, Maurizio ;

Baselga, Jose .

SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (283)

[9] Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA) [J].

Burke, John E. ;

Perisic, Olga ;

Masson, Glenn R. ;

Vadas, Oscar ;

Williams, Roger L. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (38) :15259-15264

[10] Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance [J].

Castellano, Esther ;

Sheridan, Clare ;

Thin, May Zaw ;

Nye, Emma ;

Spencer-Dene, Bradley ;

Diefenbacher, Markus E. ;

Moore, Christopher ;

Kumar, Madhu S. ;

Murillo, Miguel M. ;

Groenroos, Eva ;

Lassailly, Francois ;

Stamp, Gordon ;

Downward, Julian .

CANCER CELL, 2013, 24 (05) :617-630

← 1 2 3 4 5 6 7 8 9 →